Chesapeake Capital Corp IL Sells 3,433 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Chesapeake Capital Corp IL decreased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 25.7% in the first quarter, Holdings Channel.com reports. The firm owned 9,938 shares of the company’s stock after selling 3,433 shares during the period. Chesapeake Capital Corp IL’s holdings in Twist Bioscience were worth $341,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. ARK Investment Management LLC raised its position in shares of Twist Bioscience by 6.3% in the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock worth $265,881,000 after purchasing an additional 427,274 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Twist Bioscience by 111.3% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after buying an additional 1,961,621 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Twist Bioscience by 2.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock valued at $132,086,000 after buying an additional 99,511 shares during the last quarter. Nikko Asset Management Americas Inc. grew its holdings in shares of Twist Bioscience by 2.9% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock valued at $131,835,000 after buying an additional 99,511 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Twist Bioscience by 29.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after acquiring an additional 284,884 shares during the last quarter.

Twist Bioscience Stock Up 0.6 %

Shares of Twist Bioscience stock traded up $0.34 during trading hours on Friday, reaching $53.90. 811,154 shares of the stock traded hands, compared to its average volume of 1,017,020. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $59.54. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of -16.04 and a beta of 1.80. The company has a 50 day moving average price of $48.60 and a 200 day moving average price of $39.97.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. During the same period in the previous year, the business posted ($1.06) earnings per share. The firm’s quarterly revenue was up 25.1% compared to the same quarter last year. Sell-side analysts anticipate that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on TWST. Guggenheim initiated coverage on Twist Bioscience in a research note on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price on the stock. Robert W. Baird increased their price objective on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Scotiabank boosted their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. Evercore ISI upped their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Finally, The Goldman Sachs Group boosted their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Buy” and a consensus target price of $49.75.

Insider Activity

In related news, insider William Banyai sold 798 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $29,629.74. Following the transaction, the insider now directly owns 345,188 shares of the company’s stock, valued at approximately $12,816,830.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Twist Bioscience news, insider William Banyai sold 798 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $29,629.74. Following the sale, the insider now owns 345,188 shares in the company, valued at approximately $12,816,830.44. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Paula Green sold 910 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $33,788.30. Following the completion of the transaction, the senior vice president now owns 91,511 shares of the company’s stock, valued at $3,397,803.43. The disclosure for this sale can be found here. Insiders sold a total of 19,570 shares of company stock valued at $827,162 in the last 90 days. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.